<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01699451</url>
  </required_header>
  <id_info>
    <org_study_id>12-004718</org_study_id>
    <nct_id>NCT01699451</nct_id>
  </id_info>
  <brief_title>DNA, Blood and Skin Cell Repository for Research on ALS and Related Neurodegenerative Disorders at Mayo Clinic Florida</brief_title>
  <official_title>DNA, Blood and Skin Cell Repository for Research on ALS and Related Neurodegenerative Disorders at Mayo Clinic Florida</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to obtain clinical information and establish a repository of DNA, RNA,&#xD;
      peripheral blood monocyte, lymphocyte and skin tissue samples from people with ALS and&#xD;
      related neurodegenerative motor neuron diseases, people with a family history of these&#xD;
      conditions, and healthy people with no family history of these disorders. The samples will be&#xD;
      used in future research to learn about how these disorders affect people, what causes these&#xD;
      conditions, and how the investigators can tell when someone has this kind of disease. Future&#xD;
      research may also include the generation of stem cells from stored blood cell and skin cell&#xD;
      samples. Participants will not be paid for taking part in this study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">December 2032</completion_date>
  <primary_completion_date type="Anticipated">December 2032</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Repository sample collection</measure>
    <time_frame>once</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Amyotrophic Lateral Sclerosis (ALS)</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      This study will establish a repository of stored DNA, RNA, monocyte, lymphocyte and skin&#xD;
      fibroblast samples from people with ALS and ALS-FTD, subjects with a family history of ALS&#xD;
      who do not have ALS or ALS-FTD, and subjects with no personal history of ALS or dementia, to&#xD;
      support future translational and basic research studies on ALS and related neurodegenerative&#xD;
      disorders.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Eligible patients will be female or male, &gt; or = 18 years of age. ALS and control subjects&#xD;
        will meet eligibility criteria. Control subjects will be similar in age to ALS patients. No&#xD;
        special classes of subjects are specifically sought or excluded from the protocol.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ALS Patient&#xD;
&#xD;
               1. Clinical diagnosis of possible, laboratory-supported probable, probable or&#xD;
                  definite ALS according to modified EL Escorial criteria, suspected ALS according&#xD;
                  to original El Escorial criteria, or diagnosis of a neurodegenerative disorder&#xD;
                  with evidence of ALS plus extramotor features&#xD;
&#xD;
               2. &gt; or = 18 years of age and willing to provide consent, or assent, if unable to&#xD;
                  consent&#xD;
&#xD;
          -  Subject with family history of ALS or other relevant neurodegenerative disease&#xD;
&#xD;
               1. No personal history of ALS, ALS-FTD or other motor neuron disease&#xD;
&#xD;
               2. Family history of ALS, ALS-FTD in a first, second or third degree blood relative&#xD;
&#xD;
               3. &gt; or = 18 years of age and willing to provide consent&#xD;
&#xD;
          -  Control&#xD;
&#xD;
               1. No personal or family history (first or second degree blood relative) of ALS,&#xD;
                  dementia, Parkinson disease or other relevant neurodegenerative disorder&#xD;
&#xD;
               2. &gt; or = 18 years of age and willing to provide consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ALS Subject and subject with family history of ALS/ALS-FTD or other neurodegenerative&#xD;
             motor neuron disorder but no personal history of such conditions&#xD;
&#xD;
               1. History of medical disorder that leaves in question whether neurological signs&#xD;
                  and symptoms potentially related to a neurodegenerative disease may be&#xD;
                  contributed to by an acquired condition&#xD;
&#xD;
               2. Limited mental capacity rendering the subject unable to comply with skin punch&#xD;
                  biopsy or standard phlebotomy procedures&#xD;
&#xD;
               3. For collection of skin punch biopsy, an increased risk of bleeding complications&#xD;
                  or allergy to local anesthetic administered at the time of skin biopsy&#xD;
&#xD;
          -  Healthy Control Subject&#xD;
&#xD;
               1. Personal or family history of dementia or other neurodegenerative disease&#xD;
                  (Parkinson disease, Alzheimer disease, etc.)&#xD;
&#xD;
               2. Limited mental capacity rendering the subject unable to provide written informed&#xD;
                  consent or comply with standard phlebotomy procedures&#xD;
&#xD;
               3. For collection of skin punch biopsy, an increased risk of bleeding complications&#xD;
                  or allergy to local anesthetic administered at the time of skin biopsy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bjorn Oskarsson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 30, 2012</study_first_submitted>
  <study_first_submitted_qc>October 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2012</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Bjorn E. Oskarsson</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Neurodegenerative Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

